Evotec SE reports H1 2024 results: Challenging year; priority reset …
WEBAug 14, 2024 — Strong progress of Just – Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated. Challenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentum.
Evotec reports Q1 2024 results and provides corporate update
WEBMay 22, 2024 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced financial results and corporate updates for the first quarter 2024. HIGHLIGHTS. EVOTEC’S TRANSACTIONAL BUSINESS IMPACTED BY HEADWINDS; STRONG GROWTH IN JUST – EVOTEC BIOLOGICS.
Evotec News - Evotec Website (English)
WEBEvotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths. Evotec SE today announced its financial results and corporate updates for the first half-year of …
Evotec and Novo Nordisk Enter into Technology Development …
WEB1 day ago — Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE ...
Evotec Presents Fiscal Year 2023 Results and Announces Priority …
WEBApr 24, 2024 — The base business increased by 7% from € 714.4 m in 2022 to € 766.5 m in 2023 despite severe operational impediments in Q2 caused by the cyber-attack. Just - Evotec Biologics contributed € ...
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to …
WEB21 hours ago — Evotec’s original agreement was with Celgene, which BMS acquired in 2019 for $74 billion. In 2023, the pharma put $4 billion on the line for an expanded contract, giving it access to Evotec’s induced pluripotent stem cell platform. Last month, Evotec announced that it hit a milestone under this partnership, triggering a $25 million payment ...
Evotec Said to Tap Advisers as Slump Sparks Takeover Fears
WEBJun 20, 2024 — German drug developer Evotec SE is speaking to defense advisers after a decline in its share price prompted fears about the company’s vulnerability to a takeover, people with knowledge of the ...
EQS-News: Evotec and Novo Nordisk enter into technology …
WEB1 day ago — EQS-News: EVOTEC SE / Key word(s): Miscellaneous Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies 26.09.2024 / 07:30 CET/CEST
Buy Rating Affirmed: Evotec AG’s Anticipated Recovery and …
WEBMay 23, 2024 — Evotec AG Navigates Q1 Challenges, Eyes Growth; Centogene, Evotec discover new molecule with potential to treat Gaucher disease; Evotec price target lowered to EUR 16 from EUR 18.60 at RBC...
Investor Relations & Evotec News - Evotec Website (English)
WEBAug 13, 2024 — Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths. Evotec SE today announced its financial results and corporate updates for the first half-year of 2024. Learn more. All News.
- Some results have been removed